Terms: = Thyroid cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Treatment
190 results:
1. Functional analysis of ESM1 by shRNA-mediated knockdown of its expression in papillary thyroid cancer cells.
Xie L; He L; Zhang W; Wang H
PLoS One; 2024; 19(4):e0298631. PubMed ID: 38626010
[TBL] [Abstract] [Full Text] [Related]
2. An enzyme-free sensing platform for miRNA detection and in situ imaging in clinical samples based on DNAzyme cleavage-triggered catalytic hairpin assembly.
Wang H; Shen M; Shen X; Liu J; Huang W; Jiang X; Liu H; Zeng S; Nan K; Cai S
Biosens Bioelectron; 2024 Jul; 256():116279. PubMed ID: 38608496
[TBL] [Abstract] [Full Text] [Related]
3. Sublethal thermal stress promotes migration and invasion of thyroid cancer cells.
Kuo CY; Tsai CH; Wu JK; Cheng SP
PLoS One; 2024; 19(2):e0298903. PubMed ID: 38394093
[TBL] [Abstract] [Full Text] [Related]
4. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating ERK signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
5. RNA Profile of Cell Bodies and Exosomes Released by Tumorigenic and Non-Tumorigenic thyroid Cells.
Maggisano V; Capriglione F; Mio C; Bulotta S; Damante G; Russo D; Celano M
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338696
[TBL] [Abstract] [Full Text] [Related]
6. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
7. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary thyroid Carcinoma in a Colombian Cohort.
Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
[TBL] [Abstract] [Full Text] [Related]
8. Fasting regulates mitochondrial function through lncRNA PRKCQ-AS1-mediated IGF2BPs in papillary thyroid carcinoma.
Zhang X; Zhong Y; Liu L; Jia C; Cai H; Yang J; Wu B; Lv Z
Cell Death Dis; 2023 Dec; 14(12):827. PubMed ID: 38092752
[TBL] [Abstract] [Full Text] [Related]
9. Asiaticoside Down-Regulates HIF-1α to Inhibit Proliferation, Migration, and Angiogenesis in thyroid cancer Cells.
Zhang Y; Han Y; Dong J; Li F; Sun Y
Balkan Med J; 2024 Jan; 41(1):23-29. PubMed ID: 38044598
[TBL] [Abstract] [Full Text] [Related]
10. Customized fluorescent probe for peering into the expression of butyrylcholinesterase in thyroid cancer.
Kang W; Ma M; Xu L; Tang S; Li J; Ma P; Song D; Sun Y
Anal Chim Acta; 2023 Nov; 1282():341932. PubMed ID: 37923409
[TBL] [Abstract] [Full Text] [Related]
11. HIF-1α regulates the cell viability in radioiodine-resistant papillary thyroid carcinoma cells induced by hypoxia through PKM2/NF-κB signaling pathway.
Wang D; Liu X; Li M; Ning J
Mol Carcinog; 2024 Feb; 63(2):238-252. PubMed ID: 37861358
[TBL] [Abstract] [Full Text] [Related]
12. MiR-1284 suppresses the proliferation and migration of thyroid cancer.
Zhang L; Ge R; Cheng A; Hu T
Cell Mol Biol (Noisy-le-grand); 2023 Aug; 69(8):246-249. PubMed ID: 37715373
[TBL] [Abstract] [Full Text] [Related]
13. PIWIL2 restrains the progression of thyroid cancer via interaction with miR-146a-3p.
Lu X; Zhu Q; Du H; Gu M; Li X
BMC Endocr Disord; 2023 Aug; 23(1):184. PubMed ID: 37641092
[TBL] [Abstract] [Full Text] [Related]
14. Deltex E3 ubiquitin ligase 4 promotes thyroid cancer progression through stearoyl-CoA desaturase 1.
Cui Y; Luo J; Bai N; Yu Z
Funct Integr Genomics; 2023 Aug; 23(3):280. PubMed ID: 37612343
[TBL] [Abstract] [Full Text] [Related]
15. MEX3A induces the development of thyroid cancer via targeting CREB1.
Feng G; Wang P; Zhang H; Cheng S; Xing Y; Wang Y
Cell Biol Int; 2023 Nov; 47(11):1843-1853. PubMed ID: 37529875
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Impact of Androgen Receptor-Suppressing miR-146b Expression in Papillary thyroid cancer Aggressiveness.
Chou CK; Chi SY; Hung YY; Yang YC; Fu HC; Wang JH; Chen CC; Kang HY
J Clin Endocrinol Metab; 2023 Oct; 108(11):2852-2861. PubMed ID: 37220080
[TBL] [Abstract] [Full Text] [Related]
17. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
[TBL] [Abstract] [Full Text] [Related]
18. Overexpressed ZC3H13 suppresses papillary thyroid carcinoma growth through m6A modification-mediated IQGAP1 degradation.
Xie R; Chen W; Lv Y; Xu D; Huang D; Zhou T; Zhang S; Xiong C; Yu J
J Formos Med Assoc; 2023 Aug; 122(8):738-746. PubMed ID: 36739231
[TBL] [Abstract] [Full Text] [Related]
19. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
[TBL] [Abstract] [Full Text] [Related]
20. Reversing "Flip-Flop" Phenomenon of 131 I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory thyroid cancer Lesions After treatment of Pralsetinib.
Chan HP; Chen IF; Tsai FR; Kao CH; Shen DH
Clin Nucl Med; 2023 Mar; 48(3):e147-e148. PubMed ID: 36327463
[TBL] [Abstract] [Full Text] [Related]
[Next]
